Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for vocal cord dysfunction in severe difficult-to-treat asthma
ACTRN12611001270909Phase 4Not yet recruiting
- Sponsor
- Prof Philip Bardin
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of neuronox in vocal cord dysfunction (VCD), severe asthma, sponsored by Prof Philip Bardin. Planned start Nov 2011; status: not yet recruiting.
02
Drugs
neuronox
03
Conditions
vocal cord dysfunction (VCD)severe asthma
Beyond the preview
Go deeper on ACTRN12611001270909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611001270909.